BioCentury | Nov 10, 2014
Clinical News

ARA 290 regulatory update

...FDA granted Fast Track designation to Araim's ARA 290 to treat sarcoidosis-associated small fiber neuropathy. The short...
...is in Phase IIb testing for the indication, with Phase III testing slated for 4Q15. ARA 290...
...Drug designation in the EU and the U.S. Araim Pharmaceuticals Inc. , Ossining, N.Y. Product: ARA 290...
BioCentury | Oct 28, 2013
Clinical News

ARA 290 regulatory update

...The European Commission granted Orphan Drug designation to Araim's ARA 290 to treat sarcoidosis. The short tissue...
...for small fiber neuropathy in Type II diabetics. Araim Pharmaceuticals Inc. , Ossining, N.Y. Product: ARA 290...
BioCentury | Feb 21, 2013
Distillery Therapeutics

Indication: Dermatology

...and CD131 has been shown to decrease tissue damage. In mice with partial-thickness burn wounds, ARA 290...
BioCentury | Oct 3, 2011
Company News

Aaraim Pharmaceuticals Inc., Nanotherapeutics, Neumedicines, RxBio, The University of Arkansas for Medical Sciences other news

HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded five contracts worth up to a total of $70.7 million for the development of therapies to treat acute radiation injuries. Aaraim received $3.1 million for ARA-290,...
BioCentury | Sep 30, 2011
Company News

BARDA awards up to $70.7M for radiation therapies

HHS's Biomedical Advanced Research and Development Authority awarded five contracts worth up to a total of $70.7 million for the development of therapies to treat acute radiation injuries. Araim Pharmaceuticals Inc. (Ossining, N.Y.) received $3.1...
BioCentury | Jan 13, 2011
Targets & Mechanisms

EPO plays defense

North American researchers have shown that erythropoietin can stave off the destruction of pancreatic islet b cells in mouse models of type 1 and type 2 diabetes. 1 Although erythropoietin itself is unlikely to become...
Items per page:
1 - 6 of 6